We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Interview with the Winner of the 1st CEE Pharmaceutical Manufacturing Excellence Award
Industry Insight

Interview with the Winner of the 1st CEE Pharmaceutical Manufacturing Excellence Award

Interview with the Winner of the 1st CEE Pharmaceutical Manufacturing Excellence Award
Industry Insight

Interview with the Winner of the 1st CEE Pharmaceutical Manufacturing Excellence Award

Want a FREE PDF version of This Industry Insight?

Complete the form below and we will email you a PDF version of "Interview with the Winner of the 1st CEE Pharmaceutical Manufacturing Excellence Award"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ABB together with its customer Gedeon Richter won the 1st ever CEE Pharmaceutical Manufacturing Excellence Award in the solution provider category at PHARM Connect - the market leading pharmaceutical and biotechnology manufacturing business summit for CEE.

From left: József Ferenczi, Local Division Manager Process Automation, ABB; 
Dr. Erik Bogsch, Head of Biotechnology R&D Division, Gedeon Richter; 
Rajiv Varma, PACT Service Operations Manager, ABB

To learn more about the award winning project, TEG the organiser of PHARM Connect interviewed Istvan Pasztor, Cluster Segment Manager and Bence Tóth, Project Manager at ABB.
Bence Tóth responsible for the project has been working at ABB for 15 years. He graduated as Chemical Engineer at the Technical University of Budapest as Specialist of Chemical Process Engineering and Automation, and has more than 10 years’ experience on designing and executing batch process control projects in the pharmaceutical industry. He is a member of the ABB Batch Reference Group which helps the ABB 800xA Batch system development based on their project experiences.

TEG: Which solutions and improvements did you introduce for Gedeon Richter? 

ABB: ABB introduced a fully automated, integrated and validated production, building management and environmental monitoring system for a multipurpose and flexible batch manufacturing green field facility for mammalian cell fermentation based biological pharmaceutical production.

TEG: How did this contribute to your client’s success?

ABB: Process Automation is an essential requirement for a modern biotechnology manufacturing facility to ensure microbiological and environmental safety, an effective PAS and EMS system are key enablers in achieving that goal. PAS system allows necessary integration of technology steps, drives effectiveness and efficiency, allows required remote control of the process technology, it is a key element that makes the GR Debrecen biotechnology plant a ‘world class’ facility.

TEG: What was the innovation within your project which made you win the 1st CEE Pharmaceutical Manufacturing Excellence Award?

ABB: The innovation within the project was an effective PAS and EMS system.

TEG: How do you think the recognition is helping you to raise your brand awareness further?

ABB: It helps to build good reputation in the pharma and biotech automation market.

TEG: In your opinion, how is the award supporting the developments of manufacturing excellence solutions in the CEE region?

ABB: It can help in convincing decision makers to invest into modern technology.

TEG: From your perspective, which are the biggest challenges the pharmaceutical industry is facing nowadays in the CEE region?

ABB: Time to market, which means the time period from starting the R&D phase until the commercialisation of the medicine itself. The length of commercialisation can vary on a long scale, and has a significant bottom line impact.

Another big challenge is the tough competition in the market and the low margins, especially in the field of generic drugs due to systematic public procurement procedures by national health authorities, the black market, low-cost producers e.g. from Asia and on-line shopping. At that respect ABB could help through innovative process automation solutions and fast delivery.
Innovation and new medicines are the key for growth and survival, especially biotech is taking over, by 2020 two third of the new drugs are foreseen to come from biotech processes.

TEG: How are you supporting your clients to overcome them? 

ABB: With an international ABB Team of competent engineers and creative experts.

TEG: Are you planning to apply for the award again in the future during PHARM Connect?
ABB: Yes, certainly, it was a great honour to receive this award.

If you think your solution is cutting-edge and should be recognised by the industry, apply now for the 2nd CEE Pharmaceutical Manufacturing Excellence Award and put your business in the spotlight at the 6th PHARM Connect Congress which will take place again at 5* Corinthia Hotel in Budapest, Hungary on 24-25 February 2016.